Abiopharma

Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio

CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance

Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference

Geron Corporation Provides 2026 Financial Guidance

Geron Corporation Provides 2026 Financial Guidance

Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma

New Form SC TO-T/A - Generation Bio Co. Filed: 2026-01-12 AccNo: 0001193125-26-009808 Size: 16 KB

(99% Neutral) Orthopediatrics Corp (KIDS) Reports Q1 2026 Financial Results

(10% Negative) ProKidney Corp (PROK) Announces Delay in pathway Trials for rilparencel Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(85% Positive) Avalo Therapeutics Inc. (AVTX) Files Form 8-K

(99% Positive) Emergent Biosolutions Inc. (EBS) Files Form 8-K

(99% Positive) Krystal Biotech (KRYS) Announces Enrollment Update for sheet Due to Patient Enrollment Issues, Regulatory Process

(70% Positive) Ultragenyx Pharmaceutical Inc (RARE) Announces Enrollment Update for program Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review

(10% Negative) Summit Plc (SMMT) Announces Delay in applications Trials for marketing approvals Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment